Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Acute lymphoblastic leukemia (ALL) is a hematologic malignancy with specific genetic alterations.
• The mTOR signaling pathway is often dysregulated in various cancers, including ALL.
• Tumor suppressor genes like p14, p15, and p57 play critical roles in cell cycle regulation.

Purpose of the Study:

• To investigate the anti-leukemic effects of rapamycin on acute lymphoblastic leukemia (ALL) cells.
• To elucidate the molecular mechanisms underlying rapamycin's action in ALL.
• To explore the potential of rapamycin as a therapeutic agent for adult ALL.

Main Methods:

• Utilized ALL cell lines (Molt-4, Nalm-6) and primary ALL patient samples.
• Assessed cell viability and cell cycle progression after rapamycin treatment.
• Analyzed gene and protein expression of key regulators (p14, p15, p57, mTOR, 4E-BP1, p70S6K).
• Investigated promoter methylation status of p14, p15, and p57 genes.
• Employed siRNA to deplete mTOR and assess its role.

Main Results:

• Rapamycin significantly reduced ALL cell viability and induced G1/S phase arrest.
• Rapamycin restored expression of p14, p15, and p57 genes through promoter demethylation.
• Rapamycin decreased mTOR and p70S6K mRNA and protein levels.
• mTOR depletion did not affect the expression or methylation of p14, p15, and p57 genes.

Conclusions:

• Rapamycin exerts anti-leukemic effects in ALL cells primarily through demethylation-induced restoration of p14, p15, and p57 expression.
• Inhibition of mTOR and p70S6K signaling pathways contributes to rapamycin's efficacy.
• These findings support the potential therapeutic application of rapamycin in adult ALL treatment.